Novavax Inc (NVAX)vsBeiGene, Ltd. (ONC)
NVAX
Novavax Inc
$9.34
+0.86%
HEALTHCARE · Cap: $1.57B
ONC
BeiGene, Ltd.
$283.45
+2.81%
HEALTHCARE · Cap: $31.62B
Smart Verdict
WallStSmart Research — data-driven comparison
BeiGene, Ltd. generates 376% more annual revenue ($5.34B vs $1.12B). NVAX leads profitability with a 39.2% profit margin vs 5.4%. NVAX trades at a lower P/E of 3.7x. NVAX earns a higher WallStSmart Score of 56/100 (C).
NVAX
Buy56
out of 100
Grade: C
ONC
Hold42
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+48.9%
Fair Value
$17.54
Current Price
$9.34
$8.20 discount
Margin of Safety
-1983.5%
Fair Value
$16.86
Current Price
$283.45
$266.59 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Keeps 39 of every $100 in revenue as profit
Revenue surging 66.6% year-over-year
Conservative balance sheet, low leverage
Revenue surging 32.8% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Smaller company, higher risk/reward
ROE of -9.0% — below average capital efficiency
Earnings declined 38.1%
Negative free cash flow — burning cash
0.0% earnings growth
ROE of 7.5% — below average capital efficiency
5.4% margin — thin
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : NVAX
The strongest argument for NVAX centers on P/E Ratio, Profit Margin, Revenue Growth. Profitability is solid with margins at 39.2% and operating margin at 14.2%. Revenue growth of 66.6% demonstrates continued momentum.
Bull Case : ONC
The strongest argument for ONC centers on Revenue Growth, Debt/Equity. Revenue growth of 32.8% demonstrates continued momentum.
Bear Case : NVAX
The primary concerns for NVAX are Market Cap, Return on Equity, EPS Growth.
Bear Case : ONC
The primary concerns for ONC are EPS Growth, Return on Equity, Profit Margin. A P/E of 111.0x leaves little room for execution misses.
Key Dynamics to Monitor
NVAX profiles as a growth stock while ONC is a hypergrowth play — different risk/reward profiles.
NVAX carries more volatility with a beta of 2.63 — expect wider price swings.
NVAX is growing revenue faster at 66.6% — sustainability is the question.
ONC generates stronger free cash flow (131M), providing more financial flexibility.
Bottom Line
NVAX scores higher overall (56/100 vs 42/100), backed by strong 39.2% margins and 66.6% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novavax Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Novavax, Inc., a biotechnology company, focuses on the discovery, development and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company is headquartered in Gaithersburg, Maryland.
Visit Website →BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?